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Glycosaminoglycans (GAGs) commonly participate in herpesvirus entry. They are thought to provide a reversible attachment to
cells that promotes subsequent receptor binding. Murine gamma-herpesvirus-68 (MHV-68) infection of fibroblasts and
epithelial cells is highly GAG-dependent. This is a function of the viral gp150, in that gp150-deficient mutants are much less
GAG-dependent than wild-type. Here we show that the major MHV-68 GAG-binding protein is not gp150 but gp70, a product
of ORF4. Surprisingly, ORF4-deficient MHV-68 showed normal cell binding and was more sensitive than wild-type to inhibition
by soluble heparin rather than less. Thus, the most obvious viral GAG interaction made little direct contribution to infection.
Indeed, a large fraction of the virion gp70 had its GAG-binding domain removed by post-translational cleavage. ORF4 may
therefore act mainly to absorb soluble GAGs and prevent them from engaging gp150 prematurely. In contrast to gp70, gp150
bound poorly to GAGs, implying that it provides little in the way of adhesion. We hypothesize that it acts instead as a GAG-
sensitive switch that selectively activates MHV-68 entry at cell surfaces.
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INTRODUCTION
Glycosaminoglycans (GAGs) are ubiquitous components of mam-
malian epithelial surfaces [1], and many viruses exploit them as
entry co-factors. GAG binding is thought to allow virions to roll on
cell surfaces until they encounter a protein ligand [2]. Herpes-
viruses encode a particular abundance of GAG binding proteins.
For example, the Herpes simplex virus (HSV) glycoproteins B (gB),
C and D all bind to GAGs [3–5], as do the Kaposi’s Sarcoma-
associated Herpesvirus (KSHV) gB, ORF4 and K8.1 [6–9]. Why
these viruses should have so many GAG-binding proteins is
unclear. Each also has several cell surface protein ligands, so the
additional adhesion conferred by GAG binding would seem to be
superfluous. This puzzle over GAGs is part of a more general
conceptual challenge that the extraordinarily elaborate entry of
herpesviruses presents. While most viruses make do with a single
cell-binding glycoprotein, herpesviruses typically employ at least
four. Since herpesviruses are generally transmitted from immune
hosts, the obvious explanation for this complexity would be
antibody evasion.
GAGs have received relatively little attention in gamma-
herpesvirus infections because the archetypal gamma-herpesvirus,
Epstein-Barr virus (EBV), appears to ignore them [10]. However,
several gamma-2-herpesviruses do use GAGs for entry. Besides
KSHV, GAG binding has been reported for the Bovine
herpesvirus-4 (BHV-4) gB [11] and the Herpesvirus saimiri
ORF51 [12]. The narrow species tropisms of these viruses have
somewhat limited our understanding of how they work. Thus, the
small animal model provided by the murine gammaherpesvirus-68
(MHV-68) [13,14] provides an important experimental tool.
MHV-68 naturally infects yellow-necked mice [15] and appears
also to behave as a natural pathogen of inbred laboratory strains,
in that it persists without causing disease unless there is immune
suppression. At least 90% of its genes have clear homologs in
KSHV or EBV [16]. In order to derive the greatest benefit from
MHV-68 pathogenesis data, it is necessary to identify the protein
functions that lie behind them. For example, MHV-68 infects
epithelial cells, fibroblasts, B cells [17], macrophages [18] and
dendritic cells [19], but understanding this tropism requires an
understanding of the MHV-68 glycoproteins. Here we have
addressed how these glycoproteins interact with GAGs.
MHV-68 infection of fibroblasts is highly sensitive to inhibition
by soluble heparin [20]. We have previously characterized this
sensitivity as a function of gp150, the MHV-68 M7 gene product.
Thus, when M7 is disrupted infection is much less GAG-
dependent. However, gp150, in contrast to its KSHV and Herpes-
virus saimiri homologs, has not been shown to bind to GAGs. Nor
has GAG binding been demonstrated for any other MHV-68 gene
product. In this paper, we identify the major GAG-binding protein
of MHV-68 as gp70, a product of ORF4, previously defined as
a complement control protein [21,22]. Surprisingly, gp70-deficient
MHV-68 showed no obvious infection deficit and remained at
least as GAG-dependent as wild-type. In contrast, gp150-deficient
MHV-68 showed a marked, GAG-related phenotype but an
association of gp150 with GAGs was hard to find. We found no
evidence for the MHV-68 gB binding to GAGs, even though it has
an equivalent ‘‘GAG-binding’’ motif to KSHV and BHV-4. We
propose a model in which MHV-68 uses GAGs as a cell surface-
associated entry cue via gp150 rather than for adhesion via gp70.
The rationale is that MHV-68 can thereby minimise the exposure
of key glycoprotein epitopes to antibody.
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ORF4-specific monoclonal antibodies
Our aim was to understand the GAG dependence of MHV-68 in
the context of its GAG-binding glycoproteins. Our starting hypo-
thesis was that gp150, ORF4 and gB could all have functionally
important GAG interactions. We have previously characterized
monoclonal antibodies (mAbs) for the identification of gp150 [20]
and gB [23]. We completed this set of reagents by characterizing 5
mAbs that recognize ORF4 (Table 1). All were derived from
MHV-68-infected mice. With the exception of 9C7 (see below),
they recognized both CHO cells transfected with an ORF4
expression vector (Figure 1A) and BHK-21 cells infected with wild-
type but not ORF4-deficient MHV-68 (Figure 1B). MAbs T2B11
and T3B8 are shown as examples. MAbs 16D2 and 9C7
recognized ORF4 products in immunoblots of purified virions
(Figure 1C). The major band recognized by 16D2 had an
apparent molecular weight of 70 kDa (gp70), equivalent to the 60-
65 kDa band described by Kapadia et al. [21]. 9C7 recognized
both this band and one of 25 kDa (gp25).
MAb 9C7 recognized transfected ORF4 much like T3B8 and
T2B11 in Figure 1A (data not shown) but still stained cells infected
with ORF4-deficient MHV-68, albeit at a lower level than those
infected with wild-type (Figure 1D). Despite rigorous subcloning,
9C7 immunoprecipitated both ORF4 and gH (Figure 1E). These
proteins were not associated in the lysates, because other mAbs
precipitated them separately (Figure 1E). 9C7 also recognized
transfected gH/gL (data not shown). Other mAbs recognizing an
overlapping gH/gL epitope [13] failed to recognize ORF4 (data
not shown) and the 9C7 immunoblot signal was entirely ORF4-
specific (Figure 1C). Thus, 9C7 recognized 2 distinct MHV-68
glycoprotein epitopes, presumably via different interactions.
Table 1. ORF4-specific mAbs used in this study.
......................................................................
mAb isotype target
1
T3B8 IgG1 SCR.4
T2B11 IgM SCR.1
6H10 IgG2a SCR.1
16D2 IgG2a SCR.4
9C7 IgG2b ST
1The predicted ORF4 gene product is a type I transmembrane glycoprotein with
4 short consensus repeat (SCR) domains, followed by an ST-rich domain,
a transmembrane domain and a short cytoplasmic tail.
doi:10.1371/journal.pone.0000347.t001
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Figure 1. Identification and characterization of mAbs specific for MHV-
68 ORF4 gene products. A. MAbs from MHV-68-infected mice were used
to stain either untransfected CHO-K1 cells (CHO) or CHO-K1 cells
transfected with an ORF4 expression construct (CHO-ORF4). These cells
were not cloned. Approximately 50% of them appeared to express ORF4.
All ORF4-specific mAbs gave equivalent staining. T3B8 and T2B11 are
shown as examples. nil=secondary antibody only. B. BHK-21 cells were
r
eitherleftuninfected(UI)orinfected(18 h,2 PFU/cell)withwild-type (WT)
or ORF4-deficient (ORF4
2) MHV-68. They were then trypsinized and
analyzed for mAb binding by flow cytometry. Again, mAbs T2B11 and
T3B8 are shown as representative examples. All ORF4-specific mAbs gave
similar results except 9C7 (see D). C. Wild-type (WT) or ORF4-deficient
(ORF4
2) viruses were directly recovered from infected cell supernatants
(virus) or also purified on density gradients (virions), denatured, resolved
by SDS-PAGE and immunoblotted with mAbs 9C7 or 16D2. D. BHK-21
cells were left uninfected (UI) or infected with wild-type (WT) or ORF4-
deficient (ORF4
2) MHV-68 as in B, followed by flow cytometric analysis of
mAb binding. E. BHK-21 cells were infected (18 h, 2 PFU/cell) with wild-
type MHV-68, then labelled for 1 h with
35S-cysteine/methionine. Viral
proteins were immunoprecipitated from cell lysates with mAbs as
indicated plus protein A-sepharose. A6, B12 and B9 are subclones of
9C7. T4C5 is a gH/gL-specific mAb. nil=protein A-sepharose only. The
bands corresponding to gH and ORF4 product are indicated.
doi:10.1371/journal.pone.0000347.g001
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ORF4 processing (Figure 2).
Mapping ORF4 mAb recognition
We used GPI-linked ORF4 truncations to map the domains recog-
nized by each mAb (Figure 2). The predicted ORF4 gene product is
a type I glycoprotein with an extracellular domain comprising 4
short consensus repeats (SCRs) followed by an ST-rich segment
(Figure 2A) [17]. SCR1 was sufficient for recognition by mAbs
T2B11 and 6H10; mAbs 16D2 and T3B8 required SCR4; 9C7
required the ST domain (Figure 2B). (Whether the more N-terminal
SCRs were also required for recognition was not determined.) Thus,
the gp25 product recognized by 9C7 but not 16D2 (Figure 1C)
seemed likely to be a C-terminal fragment of gp70, including its
transmembrane and ST domains but missing SCR4. This fragment
was presumably generated by post-translational cleavage, since RT-
PCR showed no evidence of ORF4 splicing (data not shown).
Soluble and membrane bound ORF4 products
An uncharacterized 40-45 kDa ORF4 product has been detected in
506concentrated supernatants of MHV-68-infected cells [21]. MAb
16D2 readily detected a 45 kDa ORF4 gene product in the
unconcentrated supernatants of MHV-68-infected BHK-21 cells
(Figure 3A). MAb 9C7 did not detect this product (Figure 3A),
implying that it included SCR4 but not the ST domain. Thus, it
appeared that BHK-21 cells cleave gp70 between SCR4 and the ST
domain to shed a 45 kDa SCR1-4 fragment and leave the 25 kDa
ST domain in the virion membrane. Judging by 9C7 immunoblots
(Figure 1B), most of the virion gp70 was cleaved in this way.
MHV-68-infected NMuMG cells showed a slightly different
pattern, releasing ORF4 products of both 45 kDa and 55 kDa
(Figure 3A). The 55 kDa form was bound by mAb 9C7, implying
that it was generated from more C-terminal gp70 cleavage site
than the 45 kDa form. NMuMG cell-derived virions correspond-
ingly contained less gp25 (Figure 3B). Thus, NMuMG cells could
cleave gp70 in either of 2 sites to release SCRs1-4. The minor 30-
60 kDa, 9C7-reactive bands in BHK-21 cell-derived virions
(Figure 1C, 3B) and 30-40 kDa, 16D2-reactive bands in BHK-
21 cell supernatants (Figure 3A) may be the products of more N-
terminal cleavages. So while KSHV generates a soluble form of
ORF4 by alternative splicing [24], MHV-68 achieves the same
end - release of the SCR domains-by post-translational cleavage.
The gp70 ST domain is predicted to be heavily O-glycosylated.
We analyzed the contribution of glycans to the ORF4 apparent
size by treating virus lysates with PNGase F to remove N-linked
glycans or with sialidase plus O-glycanase to remove common O-
linked glycans (Figure 3C). O-glycans evidently made a substantial
contribution to the sizes of gp70 and gp25, whereas N-linked
glycans did not. The predicted molecular weight of the full-length,
unglycosylated ORF4 product is 40 kDa, so O-linked glycans,
predominantly in the ST domain (Figure 3C), contributed
approximately 30 kDa.
ORF4 encodes the major MHV-68 GAG-binding
glycoprotein
Since heparin inhibits MHV-68 infection of GAG-expressing cells
[20], we looked for evidence of GAG binding by gp70, gp150 or
gB by heparin-agarose pull-downs of virion lysates (Figure 4A).
nil
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16D2
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Figure 2. Mapping the ORF4-specific mAb targets. A. A schematic diagram of ORF4 with its 4 SCR domains, ST domain and membrane anchor,
summarizing the information from B on approximate mAb binding sites. B. 293T cells were transfected with GPI-linked ORF4 truncations. 48 h later,
the cells were trypsinized and analyzed for mAb binding by flow cytometry. nil=secondary antibody only.
doi:10.1371/journal.pone.0000347.g002
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70 kDa. The 63 kDa lysate band is bovine albumin, which does
not bind to heparin and therefore provides a control of immuno-
precipitation specificity. Specificity was further confirmed by
inhibiting precipitation with soluble heparin (Figure 4A). An MHV-
68-immune rabbit serum (Figure 4B) strongly recognized the 70 kDa
band and a 20 kDa band, but not the 150 kDa band. The 70 kDa
band was confirmed as gp70 by immunoblotting with mAbs 16D2
and 9C7 (Figure 4C). Gp25 was not detected. It therefore did not
appear to contain the gp70 heparin binding domain.
The immune rabbit serum used strongly recognizes gp150 (as
can be seen in the lysate lane of Figure 4B), so it seemed unlikely
that the 150 kDa band was gp150. This suspicion was confirmed
by immunoblotting for gp150 (Figure 4C), which showed little
signal in precipitates compared to lysates. We observed a similar
minor recovery of gN, probably due to the precipitation of residual,
non-disrupted virions. In contrast, to these trace amounts, gp70 was
enriched in precipitates compared to lysates. gB was not enriched in
precipitates (Figure 4C).
We identified the precipitated 150 kDa band by mass spectro-
metry. Its recovered peptides gave 67% coverage of ORF75c and
14% coverage of ORF75b. These ORFs are predicted to encode
tegument proteins that would not be accessible to heparin in intact
virions. The 20 kDa band was identified as the ORF65 capsid
component (67% coverage). The association of the ORF75c,
ORF75b and ORF65 gene products with heparin presumably
reflected that they normally interact with another negatively
charged polymer such as DNA. The only glycoprotein that bound
convincingly to heparin-agarose was gp70.
The N-terminal SCRs of ORF4 bind to GAGs
We used the same ORF4 truncations as in Figure 2 to identify the
GAG-binding domain of gp70, substituting a C-terminal IgG1 Fc
domain for each GPI anchor (Figure 5). The relevant plasmids
were transfected into 293T cells. Supernatants were harvested
48 h later and assayed for IgG Fc content (Figure 5A). Gp150 amino
acids1-151wasusedasacontrol.SCR1-Fcshowedminimalbinding
to BHK-21 and NMuMG cell surfaces (Figure 5B), but all the other
ORF4constructs bound well. Thus, SCRs1+2 were sufficient for cell
binding, consistent with findings for the KSHV ORF4 [21]. The
gp150 construct failed to bind.
The binding of the ORF4-Fc constructs was inhibited by soluble
heparin (Figure 5C). The full-length construct was the least suscep-
tible to inhibition, possibly reflecting multimerization. All of the
constructs containing SCRs1+2 bound much better to GAG
+
CHO cells than to the GAG-deficient CHO cell mutant pgs745
(Figure 5D). This confirmed GAG binding by gp70 and argued
against the existence of an additional cell surface ligand. The
SCR1-specific mAb T2B11 inhibited cell binding (Figure 5E),
consistent with a dominant role for SCRs1-2.
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Figure 3. Identification of ORF4 gene products. A. NMuMG epithelial cells or BHK-21 fibroblasts were infected with wild-type (WT) or ORF4-deficient
(ORF4
2) MHV-68 (2 PFU/cell). 48 h later, cells were removed by low speed centrifugation (4006g, 10 min) and virions then removed by high speed
centrifugation (20,0006g, 3 h). Supernatants were immunoblotted with mAbs 16D2 or 9C7. B. The wild-type virions from A were similarly analyzed by
SDS-PAGE and immunoblotting. Neat and 1/3 diluted lysates are shown. C. Virus from BHK-21 (B) or NMuMG cells (N) was denatured and then left
undigested (nil) or treated with PNGase F (N-gase) or sialidase plus O-glycanase (O-gase). All samples were resolved by SDS-PAGE and
immunoblotted with mAbs 9C7 or 16D2.
doi:10.1371/journal.pone.0000347.g003
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The gBs of HSV, KSHV and BHV-4 have all been reported to
bind to GAGs [2,6,11]. The MHV-68 gB shares with these a run
of cationic amino acids-considered a GAG binding motif-near its
N-terminus. However, the motif in HSV is N-terminal to the first 2
conserved gB cysteine residues, whereas in the gammaherpes-
viruses it is C-terminal (Figure 6A). A recent crystal structure of the
HSV-1 gB [25] allows computer-based homology modelling of
other herpesvirus gBs, since their basic form is conserved.
Homology modelling placed the GAG binding motif of MHV-
68 (and that of other gammaherpesviruses) at the base of gB rather
than near its crown (data not shown). The cationic residues were
also buried. They therefore seem unlikely to interact with GAGs.
Also, mutating 2 of these residues to alanines completely abrogates
MHV-68 infectivity (L. Gillet and P.G. Stevenson, unpublished
data), which would be more consistent with a major disruption of
gB folding than with the loss of a superficial GAG binding site.
We tested recombinant gB for GAG binding by expressing its
N-terminal domain (up to the furin-like cleavage site) as a fusion
with IgG1-Fc (Figure 6B). The fusion protein bound to cells
independently of heparin (Figure 6B). Cell binding by ORF4
SCRs 1-3 is shown for comparison, with a 5–10 fold inhibition of
binding by heparin, consistent with Figure 5C. Thus, in contrast to
descriptions of the KSHV and BHV-4 gBs, we found no evidence
that the MHV-68 gB binds to GAGs.
Recombinant gp150 can bind to GAGs
Gp150 amino acid residues 1-151 fused to IgG1-Fc failed to bind
to cell surfaces (Figure 5B), as did fusions of residues 1-250 and
1-450 (data not shown). (The complete gp150 extracellular domain
is 460 amino acids.) Nor was gp150 precipitated by heparin-
agarose (Figure 4). However, the striking loss of MHV-68 GAG-
dependence when gp150 is disrupted [20] strongly suggests that
gp150 and GAGs somehow interact. It was possible that we had
not observed a physical interaction because it was weak. We
therefore expressed gp150 as a fusion with GST in E.coli to look
further at cell binding. Gp150 has a predicted signal sequence of
22 amino acids. Residues 21-460 expressed very poorly with
extensive C-terminal protein degradation (data not shown). We
therefore focussed on the region 21-151. This contains many of the
cationic residues in gp150, most of which is predicted to be highly
acidic and heavily O-glycosylated. There are 3 cationic residues in
the region 41–81 and 4 in 81–151.
Each GST fusion protein was recognized in ELISAs by at least
5 different gp150-specific mAbs (data not shown). Thus, the native
conformation of each gp150 fragment appeared to be preserved.
GST-M7:21-151 and GST-M7:41-151 both bound to BHK-21
and L929 cells, whereas GST-M7:81-151 and GST-M7:108-151
did not (Figure 7A). Convincing binding required 50 mg/ml of
fusion protein; at 10 mg/ml the binding was minimal (data not
shown). The binding was inhibited by soluble heparin and by
heparitinase III treatment of the cells (Figure 7B). GST-M7:21-
151 and GST-M7:41-151 also bound to GAG
+ but not GAG
2
CHO cells (Figure 7C), whereas GST-M7:81-151 and GST-
M7:108-151 bound to neither. Thus, an N-terminal region of
gp150 was capable of GAG binding. The better binding of GST-
M7:41-151 relative to GST-M7:21-151 suggested that residues 21-
41 might inhibit GAG binding.
ORF4-deficient MHV-68 remains heparin-sensitive
We reasoned that if the GAG dependence of wild-type MHV-68
infection [20] reflected an important contribution of gp70-the
major MHV-68 heparin binding protein-then a gp70-deficient
mutant should show an infectivity deficit and resist further
inhibition by heparin. Neither was the case (Figure 8). ORF4-
deficient MHV-68 showed no significant deficit in growth
(Figure 8A) or cell binding (Figure 8B) compared to wild-type
and was more sensitive to inhibition by soluble heparin rather than
less (Figure 8C). By contrast, gp150-deficient MHV-68 had a small
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Figure 4. Identification of MHV-68 heparin binding proteins by
heparin-agarose immunoprecipitation. A. Virus from BHK-21 cells was
lysed in 1% Triton X-100 (lysate). 10% fetal calf serum is added to
stabilize the virus, so albumin appears as a prominent 63 kDa band in
the lysate. Pull-downs with heparin-agarose beads alone (-hep) or with
additional 1 mg/ml soluble heparin (+ hep) were resolved by SDS-PAGE
and stained with Coomassie R250. The prominent 150 kDa and 70 kDa
viral bands are indicated. B. The same samples were immunoblotted
with a rabbit serum raised against whole virus. At this exposure, strong
signals are seen for only the most immunogenic viral proteins. C. The
same samples were immunoblotted for ORF4 with mAbs 16D2 and 9C7,
and for gp150, gN and gB with mAbs T1A1, 3F7 and T7H9. T1A1 and
3F7 were combined in one immunoblot because their targets are
readily distinguished. The filled arrow marks gp150 and the open arrow
gN.
doi:10.1371/journal.pone.0000347.g004
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+ cells (Figure 8B) but was largely
resistant to heparin (Figure 8C).
ORF4-deficient MHV-68 was further equivalent to wild-type in
its infection of GAG
+ and GAG
2 CHO cells, whereas gp150-
deficient MHV-68 infected GAG
2 CHO cells much better
(Figure 8D). This increased infection appeared to reflect better
cell binding (Figure 8E). Since the weak interaction of gp150 with
GAGs had much greater function consequences for MHV-68
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Figure 5. Heparin binding by ORF4 gene products. A. Gp70 truncations were fused to C-terminal human IgG1 Fc and expressed by transient
transfection of 293T cells. An equivalent fusion of gp150 amino acids 1-151 was used as a control. 293T cell supernatants were immunoblotted for
fusion protein content with a human IgG Fc-specific pAb. B. The same supernatants were used to stain unfixed BHK-21 cells or NMuMG cells. Protein
binding was assayed by flow cytometry. nil=supernatant from untransfected cells. 1 of 3 equivalent experiments is shown. C. The binding of each
fusion protein to L929 cells was tested with or without soluble heparin. The fusion proteins were pre-incubated with heparin (1 h, 4uC) and then
added to the cells. The graph summarizes data similar to those shown in B, from 1 of 3 equivalent experiments, each acquiring 30,000 events per
sample. D. The binding of each Fc fusion protein to GAG
+ or GAG
2 CHO cells was assayed by flow cytometry. 1 of 2 equivalent experiments is shown.
E. Each ORF4-specific mAb was tested for its capacity to inhibit BHK-21 cell binding by each Fc fusion protein. The mAbs and Fc fusion proteins were
incubated together (1 h, 4uC) then added to cells. The cells stained with a human IgG-Fc-specific pAb. 1 of 2 equivalent experiments is shown, again
acquiring 30,000 events per sample.
doi:10.1371/journal.pone.0000347.g005
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GAGs do not promote infection by providing strong binding
themselves, but by reversing a constitutive inhibition of cell
binding imposed by gp150.
DISCUSSION
GAGs are generally thought to promote herpesvirus infections by
adsorbing virions to cell surfaces, thereby increasing their chance
of engaging key protein ligands. The interaction between MHV-
68 and GAGs appeared to be different. Gp70 bound strongly to
GAGs but played little direct role in infection, whereas gp150
bound at best weakly, yet was the major determinant of GAG
dependence. The lack of a gp70-related infection deficit could
conceivably reflect that another virion glycoprotein also binds
strongly to GAGs, but the weak binding of gp150 seemed unlikely
to fulfill such a role. Moreover, the main effect of removing gp150
was not reduced binding to GAG
+ surfaces, but increased binding
to and infection of GAG-deficient cells. We interpret these findings
as MHV-68 using GAGs as a gp150-dependent entry signal,
rather than a significant physical attachment.
Herpes virions are inevitably exposed to antibody when they
exit immune hosts. Their survival therefore depends on protecting
key glycoprotein epitopes. They do this without recourse to
antigenic variation or generalized immune suppression. Protection
is likely to depend instead on mechanisms akin to the sequential
uncoating proposed for HIV [26]. The greater transmissibility of
herpesviruses implies that their evasion is even more effective.
Indeed, antibody evasion provides a plausible rational for the
whole multi-protein complexity of herpesvirus entry. HSV-1
currently provides the most detailed picture of how this might
work at a molecular level, with glycoprotein D changing
conformation on ligand binding to activate the gB/gH/gL fusion
complex [27–29]. We hypothesize that GAGs initiate equivalent
conformational changes in gp150. Such a mechanism would not
necessarily require strong GAG binding, particularly if ligands
such as gH/gL [30] also provide attachment. Thus, gp150 could
provide a shield against antibody that is displaced only at the
plasma membrane.
Cells shed GAGs in response to a variety of stimuli, including
inflammation [1]. MHV-68 must therefore protect its entry
mechanism against premature activation by soluble GAGs, which
would expose it to neutralizing antibody. Weak GAG binding may
achive this by making gp150 interactions reversible unless a second
ligand is subsequently engaged. Such an arrangement would be
consistent with soluble heparin competitively antagonizing entry
rather than promoting it. The abundantly shed gp45/gp55
heparin-binding SCRs of ORF4 could also provide protection
by locally absorbing soluble GAGs, in addition to saturating cell-
associated GAGs to reduce virion re-capture. The increased
sensitivity of ORF4-deficient virions to inhibition by soluble
heparin-here SCR shedding should not have been a significant
factor-suggested that gp70 may also improve the selectivity of
gp150 for membrane-bound GAGs. Thus, through gp150 and
gp70 MHV-68 can both exploit GAGs as an entry signal and cope
with the attendant problems of GAG shedding and virion release.
Since GAGs are important for MHV-68 infection, it might be
expected that antibodies could neutralize virions by blocking GAG
binding. However, we have not yet found any mAbs capable of
doing so [31,32]. In fact, gp150-specific mAbs generally improved
cell binding by the M7:21-151 and M7:41-151 GST fusions,
presumably by increasing their avidity (data not shown). The only
gp70-specific mAb that inhibited GAG binding, T2B11, was an
IgM, which may therefore act by steric hindrance rather than by
binding to the GAG interaction site itself. It did not neutralize
virions (data not shown). One reason why GAG interactions might
be hard to block was suggested by the binding of the ORF75c,
ORF75b and ORF65 gene products to heparin-agarose (Figure 4).
If nuclear localization signals and nucleic acid binding sites can
comprise cationic patches sufficient to bind GAGs, antibodies
directed against such patches would be potentially auto-reactive
MHV-68 ...FRVCGVAATGETFRFDLDKTCPSTQDKKHVEGILLVYKINIVPYIFKIRRYRKIITQLTIWRGLTT
KSHV   ...FRVCSASITGELFRFNLEQTCPDTKDKYHQEGILLVYKKNIVPHIFKVRRYRKIATSVTVYRGLTE
BHV-4  ...YRVCSASSSSGELFRFDLDQTCPDTKDKKHVEGILLVLKKNIVPYIFKVRKYRKIATSVTVYRGWS
HSV-1  ...KPKKNRKPKPPKPPRPAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPPTGATVVQFEQPRRCP
A
B
no treatment heparin (100µg/mL)
ORF4 SCR.123-Fc
gB:N-Fc
M7:N151-Fc
nil
Figure 6. Heparin-independent binding by the N-terminal fragment of gB. A. Comparison of the gB regions containing the putative heparin
binding motif of 3 gamma-herpesviruses-MHV-68, KSHV and BHV-4-and HSV-1. The first 2 conserved cysteine residues of each gB are shown in large
type. B. Binding of Fc fusion proteins to NMuMG cells, pre-incubating or not (no treatment) the fusion protein with soluble heparin. gB:N-Fc is the first
423 amino acid residues of gB fused to human IgG1 Fc. 1 of 3 equivalent experiments is shown.
doi:10.1371/journal.pone.0000347.g006
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a feature of some important cellular growth factors. Thus, GAGs
may provide a relatively antibody-resistant interaction which
viruses exploit to exit and enter immune hosts.
MATERIAL AND METHODS
Monoclonal antibodies
Female BALB/c mice were were infected intranasally with MHV-
68 (2610
4) in accordance with Home Office Project Licence 80/
1579. A 10
7 PFU intraperitoneal boost was given 3–4 months
later. Spleens were harvested after a further 3 days. Splenocytes
were fused with NS0 cells and selected with azaserine (1 mg/ml)/
hypoxanthine (100 mM) [33]. MAbs were concentrated from tissue
culture supernatant by ammonium sulfate precipitation and
quantitated by ELISA using isotype-matched standards. MAbs
against gB (T7H9) [23], gp150 (T1A1) [20], gN (3F7) [33] and
gH/gL (T4C5) [30] have been described.
Viruses
ORF4-deficient [34] and gp150-deficient [20] MHV-68 mutants,
and MHV-68 with eGFP-tagged glycoprotein M [32] have been
described. The gp150 STOP mutation [20] was transferred onto
the eGFP-tagged gM background by BAC-based mutagenesis in
E.coli [34]. Virus stocks were grown and titered by plaque assay in
BHK-21 cells [35]. Infected cells and supernatants were sonicated
after harvesting, cell debris was pelleted by low-speed centrifuga-
tion (10006g, 3 min), and virions were recovered from super-
natants by high speed centrifugation (38,0006g, 90 min). To
prepare purified virions, the pelleted virions were centrifuged on
5–15% Ficoll gradients (30,0006g, 90 min), recovered as a distinct
band, pelleted (30,0006g, 90 min), sonicated, and stored at
270uC [36]. All viruses used in infectivity experiments were
plaque-assayed in parallel. Equivalent protein content was
confirmed by immunoblotting an equivalent number of PFU for
the capsid components encoded by ORF17 (data not shown).
Plasmids
The full-length ORF4 coding sequence (genomic co-ordinates
9873-11039) [37] was amplified by PCR (Hi-Fidelity PCR kit,
Roche Diagnostics Ltd), including EcoRI and XhoI restriction sites
in the respective 59 and 39primers, and cloned into the EcoRI/XhoI
sites of pMSCV-IRES-ZEO [38]. ORF4 truncations incorporat-
ing short consensus repeat (SCR) 1 (amino acid residues 1-82),
SCRs 1+2 (amino acids 1-151), SCRs 1+2+3 (amino acids 1-209),
SCRs 1+2+3+4 (amino acids 1-270), and SCRs 1+2+3+4 and the
ST domain (amino acids 1-354) were amplified with 59 AvrII-
restricted and 39 NotI-restricted primers and cloned into the XbaI/
NotI sites of pBRAD [23] to attach a C-terminal glycosyl-
phosphatidyl-inositol (GPI) membrane anchor, or into the same
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Figure 7. GAG binding by gp150 truncations fused to GST. A. BHK-21 or L929 cells were incubated with GST alone or GST fused to gp150 (=M7)
amino acid residues 21-151, 41-151, 81-151 or 108-151. Binding was detected with a biotinylated anti-GST pAb plus phycoerythrin-conjugated
streptavidin and analyzed by flow cytometry. 1 of 5 equivalent experiments is shown. B. The GST-M7:41-151 fusion was preincubated with soluble
heparin as shown before staining BHK-21 cells. These cells were pre-digested or not with heparitinase III. The effect of heparitinase III treatment on
cell surface GAGs is shown in the inset. Protein binding was analyzed by flow cytometry as in A. 1 of 3 equivalent experiments is shown. C. Binding of
the different GST-M7 fusions to GAG
+ and GAG
2 CHO cells was quantitated by flow cytometry. 1 of 3 equivalent experiments is shown.
doi:10.1371/journal.pone.0000347.g007
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2) virions were preincubated with heparin then added to BHK-21 or
NMuMG cells. 18 h later, viral eGFP expression was assayed by flow cytometry. Each value is expressed as a percentage of the eGFP expression with
untreated virus. The data are from 1 of 2 equivalent experiments. D. BHK-21, CHO GAG
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expressed eGFP from an HCMV IE1 promoter in the BAC cassette at the left end of the genome. The number of infected cells was assessed by flow
cytometric counting of eGFP
+ cells. The data are from 1 of 2 equivalent experiments. E. CHO GAG
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2 cells were exposed to gp150
+ (WT) or
gp150
2virionsthat werefluorescentbyvirtueofaneGFPtagonglycoproteinM.At thetimesshown,thecellswerewashedwithPBS toremoveunbound
virions. Virion binding was then quantitated by flow cytometry. The data are from 1 of 2 equivalent experiments.
doi:10.1371/journal.pone.0000347.g008
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sequence for amino acid residues 1-151 of gp150 was amplified
with 59 XbaI-restricted and 39 NotI-restricted primers and cloned
into the same sites of pTORSTEN. To make GST fusions of
gp150, the relevant portions of its coding sequence (amino acid
residues 21-151, 41-151, 81-151 and 108-151 were amplified by
PCR with EcoRI-restricted and XhoI-restricted 59 and 39 primers
respectively. The 39 primer also included a 66histidine tag. The
PCR products were cloned into the EcoRI and XhoI sites of pGEX-
4T-1 (APBiotech, Little Chalfont, U.K.) so as to place the gp150
fragments downstream of and in frame with GST.
Protein expression in E.coli
Plasmids derived from pGEX-4T1 were transformed into BL-21
E.coli. Expression was induced for 4 h in log phase growth with
400 mM IPTG. The E.coli were lysed in 1% Triton X-100/50 mM
TrisCl pH 7.4/150 mM NaCl/5 mM EDTA/1 mM PMSF/
5 mM N-ethyl-maleimide/Complete protease inhibitors (Roche
Diagnostics). The GST fusion proteins were precipitated with
glutathione-sepharose beads (APBiotech), washed63 in lysis buffer
and62 in Tris-saline, eluted with 50 mM glutathione, and
dialysed63 against PBS.
Cells
Baby Hamster Kidney cells (BHK-21), L929 cells, NMuMG cells,
CHO-K1 cells, the GAG-deficient CHO-K1 mutant pgs745, and
293T cells were all grown in Dulbecco’s modified Eagle medium
(Invitrogen, Paisley, U.K.) supplemented with 2 mM glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal calf
serum (PAA laboratories, Linz, Austria). CHO-K1 cells expressing
ORF4 were generated by transfection with pMSCV-ORF4-IRES-
ZEO using Fugene-6 (Roche Diagnostics Ltd., Lewes, U.K.) and
selected in 500 mg/ml Zeocin (Invitrogen Corporation, Paisley,
U.K.). 293T cells were also transfected using Fugene-6.
Immunoprecipitation and Immunoblotting
BHK-21 cells were infected with MHV-68 (2 PFU/cell, 18 h),
starved for 45 min in cysteine/methionine-free RPMI (Sigma
Chemical Co., Poole, U.K.), then labelled for 1 h with
35S-
cysteine/methionine (PerkinElmer Life Sciences, Cambridge,
U.K.) [38]. The cells were lysed on ice for 30 min in 1% Triton
X-100, 50 mM TrisCl pH 7.4, 150 mM NaCl with 1 mM PMSF
and Complete protease inhibitors (Roche Diagnostics). Insoluble
debris was pelleted by centrifugation (13,0006g, 15 min). The
lysates were then pre-cleared with protein A-sepharose and
immunoprecipitated with monoclonal antibody plus further pro-
tein-A-sepharose. The agarose beads were washed65 in lysis
buffer and heated (95uC, 5 min) in Laemmli’s buffer. The
denatured proteins were resolved by SDS-PAGE. Dried gels were
exposed to X-ray film. To immunoprecipitate viral proteins with
heparin-agarose, virions were recovered from infected BHK-21
cell supernatants by ultracentrifugation (380006g, 90 min), then
lysed as above. The lysates were incubated with heparin-agarose
beads (Sigma Chemical Co.), with or without 1 mg/ml soluble
heparin. The beads were washed65 in lysis buffer, and the
attached proteins analysed by SDS-PAGE. For total protein
staining, gels were fixed in 10% acetic acid/50% methanol and
stained with Coomassie R250. After destaining, bands of interest
were excised and analysed by MALDI fingerprinting at the
Protein and Nucleic Acids Centre, Department of Biochemistry,
Cambridge. For immunoblotting [39], the proteins were trans-
ferred to PVDF membranes (Perbio Science, Tattenhall, U.K.).
The membranes were blocked with 10% non-fat milk in PBS/
0.1% Tween-20, then incubated with MHV-68 glycoprotein-
specific mAbs or with an MHV-68-immune rabbit serum [40].
Bound antibody was detected with horseradish peroxidase-
conjugated rabbit anti-mouse IgG pAb (Dako Corporation, Ely,
U.K.) or horseradish peroxidase-conjugated donkey anti-rabbit
IgG pAb (APBiotech), followed by washing in PBS/0.1% Tween-
20, development with ECL substrate (APBiotech) and exposure to
X-ray film. Immunoblotting of secreted proteins or virion proteins
followed a similar protocol. IgG1-Fc fusion proteins were detected
with a horseradish peroxidase-conjugated goat anti-human IgG-Fc
pAb (Sigma Chemical Co.). Where indicated, proteins were
deglycosylated before immunoblotting with PNGase F or sialida-
se+O-glycanase (Prozyme, San Leandro, CA).
Flow cytometry and immunofluorescence
Cells were incubated with glycoprotein-specific mAbs (1 h, 4uC),
washed62 in PBS, incubated with fluorescein-conjugated rabbit
anti-mouse IgG pAb (Dako Cytomation, Ely, U.K.), washed62,
and analysed on a FACS Calibur (BD Biosciences, Oxford, U.K.).
The binding of Fc fusion proteins was detected with a phycoery-
thrin-conjugated goat anti-human IgG-Fc pAb (Sigma Chemical
Co.). The binding of GST fusion proteins was detected with
a biotinylated goat anti-GST pAb (Santa Cruz Biochemicals,
Santa Cruz, CA) followed by phycoerythrin-conjugated streptavi-
din (BD Biosciences). Graphs were plotted with FCSPress v1.3.
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